GSA Capital Partners LLP Takes $445,000 Position in PTC Therapeutics, Inc. (PTCT)
GSA Capital Partners LLP purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 24,300 shares of the biopharmaceutical company’s stock, valued at approximately $445,000. GSA Capital Partners LLP owned approximately 0.07% of PTC Therapeutics as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Alps Advisors Inc. lifted its position in PTC Therapeutics by 5.6% in the 2nd quarter. Alps Advisors Inc. now owns 31,191 shares of the biopharmaceutical company’s stock valued at $572,000 after acquiring an additional 1,667 shares in the last quarter. Oppenheimer & Co. Inc. lifted its position in PTC Therapeutics by 75.1% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 42,593 shares of the biopharmaceutical company’s stock valued at $781,000 after acquiring an additional 18,273 shares in the last quarter. American International Group Inc. lifted its position in PTC Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 20,480 shares of the biopharmaceutical company’s stock valued at $202,000 after acquiring an additional 1,355 shares in the last quarter. AXA bought a new position in PTC Therapeutics in the 1st quarter valued at about $103,000. Finally, Boxer Capital LLC bought a new position in PTC Therapeutics in the 1st quarter valued at about $14,760,000. 81.30% of the stock is currently owned by institutional investors and hedge funds.
PTC Therapeutics, Inc. (NASDAQ:PTCT) opened at 17.83 on Friday. PTC Therapeutics, Inc. has a 52-week low of $4.03 and a 52-week high of $22.00. The firm’s 50 day moving average is $19.59 and its 200 day moving average is $16.40. The company’s market cap is $736.45 million.
PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.45. The firm had revenue of $47.96 million for the quarter, compared to the consensus estimate of $28.78 million. PTC Therapeutics had a negative net margin of 88.43% and a negative return on equity of 81.84%. The business’s revenue was up 206.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.14) earnings per share. Analysts forecast that PTC Therapeutics, Inc. will post ($2.35) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “GSA Capital Partners LLP Takes $445,000 Position in PTC Therapeutics, Inc. (PTCT)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/13/gsa-capital-partners-llp-takes-445000-position-in-ptc-therapeutics-inc-ptct.html.
Several equities analysts recently weighed in on PTCT shares. Citigroup Inc. reaffirmed a “buy” rating and issued a $28.00 price target on shares of PTC Therapeutics in a research report on Wednesday, September 27th. ValuEngine cut shares of PTC Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 7th. Barclays PLC reaffirmed a “hold” rating and issued a $22.00 price target on shares of PTC Therapeutics in a research report on Friday, September 8th. Zacks Investment Research cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of PTC Therapeutics in a research report on Friday, September 29th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $17.11.
PTC Therapeutics Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).
Receive News & Stock Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related stocks with our FREE daily email newsletter.